Get the Stockscreener App
1.32
4.35%
-0.06
Igm Biosciences Inc stock is traded at $1.32, with a volume of 137.95K.
It is down -4.35% in the last 24 hours and up +4.76% over the past month.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
See More
Previous Close:
$1.38
Open:
$1.35
24h Volume:
137.95K
Relative Volume:
0.55
Market Cap:
$76.51M
Revenue:
$2.91M
Net Income/Loss:
$-220.40M
P/E Ratio:
-0.3626
EPS:
-3.64
Net Cash Flow:
$-176.15M
1W Performance:
+8.20%
1M Performance:
+4.76%
6M Performance:
-92.16%
1Y Performance:
-82.75%
1-Day Range:
$1.31
$1.395
1-Week Range:
$1.22
$1.47
52-Week Range:
$0.92
$22.50
Igm Biosciences Inc Stock (IGMS) Company Profile
Name
Igm Biosciences Inc
Sector
Industry
Phone
650-965-7873
Address
325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW
Compare IGMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGMS
Igm Biosciences Inc
|
1.32 | 76.51M | 2.91M | -220.40M | -176.15M | -3.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-10-25 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-10-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-10-25 | Downgrade | Stifel | Buy → Hold |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-01-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-24 | Downgrade | Truist | Buy → Hold |
| Feb-09-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-22 | Resumed | Jefferies | Buy |
| Oct-17-22 | Initiated | JP Morgan | Neutral |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Dec-13-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-21 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-26-21 | Initiated | Morgan Stanley | Overweight |
| Jan-29-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-22-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-17-20 | Initiated | Robert W. Baird | Outperform |
| Jul-01-20 | Initiated | H.C. Wainwright | Buy |
| May-28-20 | Initiated | SunTrust | Buy |
| Apr-22-20 | Initiated | Wedbush | Outperform |
| Oct-14-19 | Initiated | Guggenheim | Buy |
| Oct-14-19 | Initiated | Jefferies | Buy |
| Oct-14-19 | Initiated | Piper Jaffray | Overweight |
| Oct-14-19 | Initiated | Stifel | Buy |
View All
Igm Biosciences Inc Stock (IGMS) Latest News
Igm biosciences principal accounting officer sells $1,907 in stock - MSN
Fierce Biotech Layoff Tracker 2025: Mural lays off 90%; Tempest cuts 80% of roles - Fierce Biotech
IGMS stock touches 52-week low at $1 amid sharp annual decline - Investing.com
IGMS stock touches 52-week low at $1 amid sharp annual decline By Investing.com - Investing.com South Africa
IGM Bio stock slips as Bank of America downgrades (IGMS:NASDAQ) - Seeking Alpha
Short Interest in IGM Biosciences, Inc. (NASDAQ:IGMS) Decreases By 19.3% - MarketBeat
IGMS STOCK ALERT: Levi & Korsinsky Notifies IGM Biosciences, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
IGMS stock plunges to 52-week low at $1.14 amid market challenges - Investing.com Australia
IGMS stock plunges to 52-week low at $1.14 amid market challenges By Investing.com - Investing.com South Africa
Charles Schwab Investment Management Inc. Buys 9,441 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Up 5.9%What's Next? - MarketBeat
IGM Biosciences stock plunges to 52-week low of $1.59 - MSN
IGM Biosciences, Inc. (NASDAQ:IGMS) Given Average Rating of "Reduce" by Brokerages - MarketBeat
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives $5.50 Consensus PT from Brokerages - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Up 5.9% – Here’s Why - Defense World
Sanofi Advances Immunology Ambitions With Dren Deal - insights.citeline.com
IGM Biosciences CEO Mary Beth Harler sells $9,014 in stock By Investing.com - Investing.com Australia
IGM Biosciences CFO Tahir Misbah sells shares worth $9,014 By Investing.com - Investing.com South Africa
IGM Biosciences chief business officer sells $5,549 in stock By Investing.com - Investing.com South Africa
IGM Biosciences CEO Mary Beth Harler sells $9,014 in stock - Investing.com India
IGM Biosciences chief business officer sells $5,549 in stock - Investing.com India
IGM Biosciences CFO Tahir Misbah sells shares worth $9,014 - Investing.com India
Igm biosciences officer sells shares worth $2,092 - Investing.com India
Igm biosciences officer sells shares worth $2,092 By Investing.com - Investing.com Australia
IGM Biosciences stock plunges to 52-week low at $1.17 By Investing.com - Investing.com Australia
IGM Biosciences stock plunges to 52-week low at $1.17 - Investing.com India
IGM Biosciences Faces Uncertainty Amid Cash Preservation and Restructuring Efforts - TipRanks
IGM Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
IGM Biosciences Inc. (IGMS) reports earnings - qz.com
Contrasting IGM Biosciences (NASDAQ:IGMS) and Gyre Therapeutics (NASDAQ:GYRE) - Defense World
IGM Biosciences stock plunges to 52-week low of $1.25 By Investing.com - Investing.com Australia
IGM Biosciences stock plunges to 52-week low of $1.25 - Investing.com India
IGM Biosciences Inc expected to post a loss of 74 cents a shareEarnings Preview - TradingView
IGM Biosciences (IGMS) Projected to Post Quarterly Earnings on Thursday - MarketBeat
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - MSN
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Rating of “Reduce” from Brokerages - Defense World
Igm Biosciences Inc Stock (IGMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):